Cardiff Oncology (CRDF) to Release Quarterly Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.1210 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Cardiff Oncology Stock Down 1.7%

Cardiff Oncology stock opened at $2.31 on Tuesday. The company has a market capitalization of $153.68 million, a PE ratio of -2.66 and a beta of 1.68. The firm has a fifty day simple moving average of $2.16 and a two-hundred day simple moving average of $2.81. Cardiff Oncology has a twelve month low of $1.90 and a twelve month high of $5.64.

Hedge Funds Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently modified their holdings of CRDF. Engineers Gate Manager LP purchased a new position in shares of Cardiff Oncology during the second quarter valued at about $43,000. BNP Paribas Financial Markets increased its position in shares of Cardiff Oncology by 335.1% during the second quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock valued at $49,000 after buying an additional 11,889 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after buying an additional 4,232 shares during the period. Invesco Ltd. increased its position in shares of Cardiff Oncology by 24.9% during the second quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock valued at $75,000 after buying an additional 4,749 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Cardiff Oncology by 50.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock valued at $108,000 after buying an additional 11,497 shares during the period. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th. LADENBURG THALM/SH SH assumed coverage on shares of Cardiff Oncology in a research note on Tuesday, July 8th. They set a “buy” rating and a $19.00 price objective for the company. Finally, HC Wainwright lowered their price objective on shares of Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.63.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.